Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A
{{output}}
Introduction Triple negative breast cancer (TNBC) represents a heterogeneous subtype of breast cancer that carries a poorer prognosis. There remains a need to identify novel drivers of TNBC, which may represent targets to treat the disease. c-Met overexpressio... ...
